Wilkin TJ - Search Results

1

Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.

Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW. Cillo AR, et al. Among authors: wilkin tj. AIDS. 2015 Oct 23;29(16):2121-9. doi: 10.1097/QAD.0000000000000810. AIDS. 2015. PMID: 26544577 Free PMC article. Clinical Trial.

2

Advances in antiretroviral therapy.

Albrecht MA, Wilkin TJ, Coakley EP, Hammer SM. Albrecht MA, et al. Among authors: wilkin tj. Top HIV Med. 2003 May-Jun;11(3):97-127. Top HIV Med. 2003. PMID: 12837969 Review. No abstract available.

3

Antiretroviral Therapy: When and What to Start-- An American Perspective.

Wilkin TJ, Gulick RM. Wilkin TJ, et al. Curr Infect Dis Rep. 2003 Aug;5(4):339-348. doi: 10.1007/s11908-003-0012-z. Curr Infect Dis Rep. 2003. PMID: 12866986

4

Antiretroviral therapy: when and what to start-- an American perspective.

Wilkin TJ, Gulick RM. Wilkin TJ, et al. Curr HIV/AIDS Rep. 2004 Jun;1(2):59-67. doi: 10.1007/s11904-004-0009-8. Curr HIV/AIDS Rep. 2004. PMID: 16091224 Review.

5

Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.

Ameli N, Bacchetti P, Morrow RA, Hessol NA, Wilkin T, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM. Ameli N, et al. AIDS. 2006 Apr 24;20(7):1051-8. doi: 10.1097/01.aids.0000222078.75867.77. AIDS. 2006. PMID: 16603858

6

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team. Swindells S, et al. JAMA. 2006 Aug 16;296(7):806-14. doi: 10.1001/jama.296.7.806. JAMA. 2006. PMID: 16905786 Clinical Trial.

7

Switching antiretroviral therapy: why, when and how.

Wilkin T, Glesby M, Gulick RM. Wilkin T, et al. IAPAC Mon. 2006 Jul;12(7):220-9. IAPAC Mon. 2006. PMID: 17096494 No abstract available.

8

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. Wilkin TJ, et al. Clin Infect Dis. 2007 Feb 15;44(4):591-5. doi: 10.1086/511035. Epub 2007 Jan 17. Clin Infect Dis. 2007. PMID: 17243065

9

Advances in antiretroviral therapy.

Jones J, Taylor B, Wilkin TJ, Hammer SM. Jones J, et al. Among authors: wilkin tj. Top HIV Med. 2007 Apr-May;15(2):48-82. Top HIV Med. 2007. PMID: 17485787

10

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team. Gulick RM, et al. Among authors: wilkin tj. J Infect Dis. 2007 Jul 15;196(2):304-12. doi: 10.1086/518797. Epub 2007 Jun 5. J Infect Dis. 2007. PMID: 17570119 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page